Results 41 to 50 of about 145,724 (263)

Left Ventricular Dimension after Mitral Valve Surgery in Rheumatic Mitral Stenosis: the Impact of Myocardial Fibrosis

Journal of Tehran University Heart Center, 2020
Background: Patients with rheumatic mitral stenosis (MS) experience changes in left ventricular (LV) dimensions after mitral valve surgery. We sought to investigate changes in LV dimensional parameters after mitral valve surgery and find out whether the ...
Teuku Muhammad Haykal Putra, Renan Sukmawan, Dwita Rian Desandri, Celly Atmadikoesoemah, Elen Elen, Manoefris Kasim   +5 more
doaj   +1 more source

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit, Chiranth K. Nagaraj, Jackson S. Newell, Kim Truc Nguyen, Xilal Y. Rima, Jacob Doon‐Ralls, Eduardo Reátegui, Jeffrey M. Statland, Rabi Tawil, Kevin M. Flanigan, Scott Q. Harper, Nizar Y. Saad   +11 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Targeting inhibition of the inflammatory response: advances in the treatment of myocardial fibrosis with natural medicine and active ingredients

Frontiers in Cardiovascular Medicine
Myocardial fibrosis is a critical pathological foundation of cardiovascular diseases and a fundamental process underlying myocardial remodeling. The inflammatory response is a key driver of myocardial fibrosis, promoting the proliferation of myocardial ...
Chang Shu, Chunzhen Ren, Qilin Chen, Yanyun Wang, Ruochen Li, Yue Zhang, Shuyu Yang, Ci Wang, Ci Wang, Yingdong Li   +9 more
doaj   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

Arthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos, José Miguel Sequí‐Sabater, Diego Benavent   +2 more
wiley   +1 more source

Research Progress of Mitochondrial Autophagy in Improving Myocardial Fibrosis after Myocardial Infarction and Intervention of Traditional Chinese Medicine [PDF]

Zhongguo quanke yixue
Mitochondria, as the guardians of cells, have complex physiological functions in living organisms. Mitochondrial autophagy, as a selective autophagy method, plays a crucial role in clearing damaged mitochondria, maintaining the quantity and function of ...
ZHU Ziyi, HE Guixin, QIN Weibin, SONG Hui, ZHANG Liwen, TANG Weizhi, YANG Feifei, LIU Lingyun, OUYANG Bin
doaj   +1 more source

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

Arthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa, Yicheng Mu, Marie Hudson, Janet Pope   +3 more
wiley   +1 more source

The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort

Arthritis Care &Research, EarlyView.
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo, Ashish P. Balar, Aidan K. Strother, Subhash Kulkarni, Michael Hughes, Brian Skaug, Maureen D. Mayes, Shervin Assassi, Ali Y. Ayla, Zsuzsanna H. McMahan   +9 more
wiley   +1 more source

Recent Progresses in the Multimodality Imaging Assessment of Myocardial Fibrosis

Reviews in Cardiovascular Medicine
Myocardial fibrosis, a common pathophysiological consequence of various cardiovascular diseases, is characterized by fibroblast activation and excessive deposition of extracellular matrix (ECM) collagen.
Han Zhu, Kewei Xie, Yingying Qian, Zhiguo Zou, Meng Jiang, Jun Pu   +5 more
doaj   +1 more source

Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure

Frontiers in Physiology, 2017
Myocardial fibrosis is an important part of cardiac remodeling that leads to heart failure and death. Myocardial fibrosis results from increased myofibroblast activity and excessive extracellular matrix deposition.
Tong Liu, Deli Song, Jianzeng Dong, Pinghui Zhu, Jie Liu, Jie Liu, Wei Liu, Xiaohai Ma, Lei Zhao, Shukuan Ling   +9 more
doaj   +1 more source